Trials / Completed
CompletedNCT03518060
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 209 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a prospective, non-interventional, single-arm, multi-center study aimed at gathering real-world data on JULUCA use in routine clinical care in Germany, to supplement clinical trial data to further improve/optimize care in HIV positive participants in Germany. Approximately 250 virologically suppressed HIV positive participants on stable antiretroviral therapy (ART) were included in the study at the discretion of treating physician. Eligible participants were followed up for approximately 3 years and data was collected during routine clinical care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JULUCA | JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI). |
Timeline
- Start date
- 2018-06-25
- Primary completion
- 2023-05-14
- Completion
- 2023-05-14
- First posted
- 2018-05-08
- Last updated
- 2024-10-16
- Results posted
- 2024-10-16
Locations
23 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03518060. Inclusion in this directory is not an endorsement.